Mar312020 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 March 31, 2020
Feb242020 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) February 24, 2020
Feb62020 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study Updates February 6, 2020
Feb32020 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome February 3, 2020
Jan302020 Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 January 30, 2020
Jan272020 Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial January 27, 2020
Jan82020 Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis January 8, 2020
Dec162019 Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates December 16, 2019
Dec102019 Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 December 10, 2019
Dec42019 Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference December 4, 2019
Nov142019 Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome November 14, 2019
